vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and CaliberCos Inc. (CWD). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $3.9M, roughly 1.0× Citius Pharmaceuticals, Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -238.2%, a 49.9% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
CTXR vs CWD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.1M |
| Net Profit | $-9.4M | $-7.7M |
| Gross Margin | 80.0% | — |
| Operating Margin | -228.7% | -196.6% |
| Net Margin | -238.2% | -188.3% |
| Revenue YoY | — | -52.5% |
| Net Profit YoY | 8.6% | 32.2% |
| EPS (diluted) | $-0.38 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.1M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $5.1M | ||
| Q1 25 | — | $7.3M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | — | $8.2M | ||
| Q1 24 | — | $23.0M |
| Q4 25 | $-9.4M | $-7.7M | ||
| Q3 25 | — | $-4.4M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | — | $146.0K | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | 80.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -228.7% | -196.6% | ||
| Q3 25 | — | -129.6% | ||
| Q2 25 | — | -112.4% | ||
| Q1 25 | — | -62.7% | ||
| Q4 24 | — | -236.8% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | -65.0% | ||
| Q1 24 | — | -22.9% |
| Q4 25 | -238.2% | -188.3% | ||
| Q3 25 | — | -120.2% | ||
| Q2 25 | — | -104.5% | ||
| Q1 25 | — | -60.7% | ||
| Q4 24 | — | -247.6% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | -57.8% | ||
| Q1 24 | — | -16.6% |
| Q4 25 | $-0.38 | $1.95 | ||
| Q3 25 | — | $-1.65 | ||
| Q2 25 | — | $-4.15 | ||
| Q1 25 | — | $-3.85 | ||
| Q4 24 | — | $-10.15 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $-4.34 | ||
| Q1 24 | — | $-3.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $1.3M |
| Total Assets | $140.4M | $135.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $2.9M | ||
| Q3 25 | — | $10.9M | ||
| Q2 25 | — | $683.0K | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $80.0M | $1.3M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | — | $-19.9M | ||
| Q1 25 | — | $-15.8M | ||
| Q4 24 | — | $-12.6M | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-745.0K |
| Q4 25 | $140.4M | $135.4M | ||
| Q3 25 | — | $82.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | — | $103.6M | ||
| Q4 24 | — | $105.5M | ||
| Q3 24 | — | $158.6M | ||
| Q2 24 | — | $195.2M | ||
| Q1 24 | — | $201.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-12.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-12.1M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.7M | ||
| Q4 24 | — | $555.0K | ||
| Q3 24 | — | $-74.0K | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
